PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does PharmaEngine (4162) operate in?
PharmaEngine belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PharmaEngine (4162) current stock price?
As of the latest data, PharmaEngine stock price is NT$62.10, with a previous close of NT$63.60. PharmaEngine lost -NT$1.50 in the last trading session, representing a -2.36% loss.
What is PharmaEngine (4162) current market capitalization?
PharmaEngine market cap is approximately 8.92 billion.
What is PharmaEngine (4162) Earnings Per Share (EPS)?
The trailing EPS is NT$2.93.
What is PharmaEngine (4162) Price-to-Earnings (P/E) ratio?
PharmaEngine current P/E ratio is 21.19.
Does PharmaEngine (4162) pay dividends?
Yes. PharmaEngine pays annual dividends with an annualized yield of 9.66% and an estimated annual payout of NT$6.00 per share.
When is the next ex-dividend date for PharmaEngine (4162)?
The next ex-dividend date is scheduled for August 13, 2026.
What is PharmaEngine (4162) beta (volatility) score?
PharmaEngine has a beta of 0.145, indicating lower volatility than the overall market.